| Framingham Center For Healing Llc | |
|
50 Lexington St # 2 Framingham MA 01702-8219 | |
| (508) 561-4966 | |
| (508) 872-1132 |
| Full Name | Framingham Center For Healing Llc |
|---|---|
| Speciality | Counselor |
| Location | 50 Lexington St # 2, Framingham, Massachusetts |
| Authorized Official Name and Position | Anita Riley (LICSW) |
| Authorized Official Contact | 5085614966 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Framingham Center For Healing Llc 50 Lexington St # 2 Framingham MA 01702-8219 Ph: (508) 561-4966 | Framingham Center For Healing Llc 50 Lexington St # 2 Framingham MA 01702-8219 Ph: (508) 561-4966 |
| NPI Number | 1063879237 |
|---|---|
| Provider Enumeration Date | 01/19/2016 |
| Last Update Date | 01/19/2016 |
| Medicare PECOS PAC ID | 8426352568 |
|---|---|
| Medicare Enrollment ID | O20160210000057 |
News Archive
Nature News examines potential funding reforms for the Consultative Group on International Agriculture Research (CGIAR), which are under discussion at a the Global Conference on Agricultural Research for Development (GCARD) in Montpellier, France. The CGIAR "supports thousands of scientists working on agriculture and food security in developing countries," according to Nature News.
NaviNet, America's largest real-time healthcare communications network, announced that two of its senior executives will join industry peers in panel discussions at America's Health Insurance Plans Institute 2010. James Bogdan, senior vice president, will speak on the roles and opportunities for payers in Health Information Exchange, and Tom Morrison, co-founder and chief strategy officer, will discuss the use of multi-payer portals to improve administrative efficiencies in healthcare.
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063879237 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | 113071 (Massachusetts) | Primary |
| Provider Name | Anita Riley |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1982765012 PECOS PAC ID: 6709969298 Enrollment ID: I20080206000540 |
News Archive
Nature News examines potential funding reforms for the Consultative Group on International Agriculture Research (CGIAR), which are under discussion at a the Global Conference on Agricultural Research for Development (GCARD) in Montpellier, France. The CGIAR "supports thousands of scientists working on agriculture and food security in developing countries," according to Nature News.
NaviNet, America's largest real-time healthcare communications network, announced that two of its senior executives will join industry peers in panel discussions at America's Health Insurance Plans Institute 2010. James Bogdan, senior vice president, will speak on the roles and opportunities for payers in Health Information Exchange, and Tom Morrison, co-founder and chief strategy officer, will discuss the use of multi-payer portals to improve administrative efficiencies in healthcare.
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 1 days ago
News Archive
Nature News examines potential funding reforms for the Consultative Group on International Agriculture Research (CGIAR), which are under discussion at a the Global Conference on Agricultural Research for Development (GCARD) in Montpellier, France. The CGIAR "supports thousands of scientists working on agriculture and food security in developing countries," according to Nature News.
NaviNet, America's largest real-time healthcare communications network, announced that two of its senior executives will join industry peers in panel discussions at America's Health Insurance Plans Institute 2010. James Bogdan, senior vice president, will speak on the roles and opportunities for payers in Health Information Exchange, and Tom Morrison, co-founder and chief strategy officer, will discuss the use of multi-payer portals to improve administrative efficiencies in healthcare.
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
Sucralose, a widely used artificial sweetener sold under the trade name Splenda®, is metabolized in the gut, producing at least two fat-soluble compounds, according to a recent study using rats.
› Verified 1 days ago
Charasmatic Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 945 Concord St, Framingham, MA 01701 Phone: 774-462-8775 | |
Gateway Counseling Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5 Edgell Rd, Suite 24, Framingham, MA 01701 Phone: 508-879-7908 Fax: 508-879-1515 | |
Wayside Youth & Family Support Network Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 88 Lincoln St, Framingham, MA 01702 Phone: 508-620-0010 | |
Real Talk Private Practice, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 82 Concord St Ste 2c, Framingham, MA 01702 Phone: 774-777-6007 | |
Nulife Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 130 Worcester Rd, Framingham, MA 01702 Phone: 508-203-6770 | |
Riverside Community Care Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 385 Grant St, Framingham, MA 01702 Phone: 508-887-6424 |